Alzheimer’s disease is increasingly in the spotlight after a number of high-profile clinical trial failures—an alarming trend as an estimated 5.5 million adult Americans live with this disease, which disproportionally affects the aged population. Because the over-65 population is projected to double by 2050, the number of new cases of Alzheimer’s and related dementias is expected to soar. Consequently, Alzheimer’s disease is projected to overwhelm the national health care system, affecting 16 million Americans and costing Medicare and Medicaid $1.1 trillion by 2050. Yet, the stark reality remains that no therapeutic has been approved to prevent, slow, or cure Alzheimer’s disease. 

An infusion of philanthropic funds can de-risk a sector and demonstrate a proof-of-concept. Philanthropy can act where other entities cannot—bridging sectors without consideration of partisanship, bottom lines, or policy stances, and providing support where it is most needed.

As one of the center's critical studies, "Alzheimer's Disease - A Giving Smarter Guide" provides deep scientific insight into the issues and outlines a concrete and actionable set of options. We welcome feedback regarding our findings, as well as partners in our quest to advance scientific knowledge through philanthropy.